ERAP1 and endometrial carcinoma: Moreover, in animal studies, ERAP1-overexpression by endometrial carcinoma cells leads to a reduction in both VEGF immunoreactivity and the number of blood vessels within tumors, implicating ERAP1 in the modulation of endothelial cell migration and VEGF-induced angiogenesis (Mehta et al., 2015).